Baxter International said it agreed to acquire Cheetah Medical, the developer of a noninvasive fluid management monitoring system called the Starling SV for up to $230 million. The device’s sensor pads are applied to the chest, enabling clinicians to assess heart function and fluid responsiveness to determine the amount needed for the individual patient to maintain optimal organ and tissue perfusion. The technology is designed for use in critical care, operating room and emergency department settings. Baxter agreed to pay $190 million in cash for Cheetah, plus an additional $40 million to be paid upon achievement of clinical and commercial milestones.
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
AI Alzheimer antibodies bacteria binx health Biosimilar Blood Filter Cancer cardiovascular cell therapy CE Mark clinical trial colorectal cancer Diagnostics Digital Health Drug Discovery ExThera Medical FDA FDA approval funding fundraising glycosylation Halodoc HIV Innovation Licensing M&A medical device medtech microbial microbial DNA microbial RNA microbiome Neuro Novartis pharma Pharming Prescient Metabiomics robots software Therapeutics Therapy USA VIrology women health